BTG International Limited v. Amneal Pharmaceuticals LLC, No. 19-1147 (Fed. Cir. May 14, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellants BTG International Limited et al. (“Appel- lants”) sued Appellees Amneal Pharmaceuticals LLC et al. BTG INTERNATIONAL LIMITED v. AMNEAL PHARMACEUTICALS LLC 6 (“Appellees”) in the U.S. District Court for the District of New Jersey (“District Court”), asserting that Appellees’ Ab- breviated New Drug Applications (“ANDA”) for the generic version of Appellants’ abiraterone product ZYTIGA® in- fringes claims 1–20 (“Asserted Claims”) of U.S. Patent No. 8,822,438 (“the ’438 patent”). Subsequently, Appellees Amerigen Pharmaceuticals, Inc.